To estimate whether continuous oral contraceptive pills (OCPs) will result in more pain relief in primary dysmenorrhea patients than cyclic OCPs, which induce withdrawal bleeding with associated pain and symptoms.
quence. 1 This has both psychological and economic effects, because the resulting absenteeism causes severe economic loss each month. In one study, dysmenorrhea accounted for 600 million lost work hours and $2 billion annually in the United States. 2 Primary dysmenorrhea is most commonly attributable to excess prostaglandin production at the time of menstruation. Prostaglandin overproduction causes abnormal uterine contractions and increased intrauterine pressure, vasoconstriction of small uterine vessels leading to decreased uterine blood flow, increased sensitivity of pain receptors, and ischemia of the uterine muscle, which consequently contribute to pelvic pain. 3, 4 During uterine contractions, endometrial blood flow decreases, indicating that ischemia caused by the hypercontractility is the primary cause of the pain. 3, 5 Preventing menstruation thus may be a viable treatment option.
Oral contraceptives are frequently prescribed for this condition, but they are not always effective. 6 We theorized that cyclic oral contraceptive pills (OCPs) that induce withdrawal bleeding occasionally allow the production of prostaglandins and persistent pain. Continuous OCPs have not been studied as a primary treatment of primary dysmenorrhea, although recent studies show their superiority to cyclic regimens in the treatment of endometriosis. [7] [8] [9] We hypothesized that continuous administration of OCPs will result in more pain relief than cyclic 21 days of active pills and 7 days of placebo pills administered in primary dysmenorrhea patients. We hypothesized secondarily that the differences in uterine artery pulsatility index measured by color Doppler ultrasonography would be significant between treatment groups at the end of the trial period, compared with the beginning of the trial, and that the patient self-evaluation of menstrual symptoms as determined by a standardized questionnaire would be more favorable in the continuous group compared with the cyclic 21-7 regimen group.
MATERIALS AND METHODS
The study was approved by the Institutional Review Board at Penn State Hersey Medical Center and by the Ethics Committee at Nova Gradiska General Hospital, Croatia, where it was conducted. Participants were recruited from the obstetrics and gynecology department at Nova Gradiska General Hospital from December 2007 to May 2010. A number of women who participated in the study were presenting for their annual screening and reporting dysmenorrhea, whereas others were referred to the clinic for evaluation of dymenorrhea. All participants gave written informed consent.
We conducted a double-blind, randomized, controlled trial of two treatment regimens of monophasic OCPs (gestodene 0.075 mg and ethinyl estradiol [E2] 20 micrograms) in 38 primary dysmenorrhea patients with an allocation ratio of 1:1. The randomization list was created by our biostatistician at Penn State (A.R.K.), who sent the list to the certified research pharmacy in Croatia (Magdis, Sveta Nedjelja) and who overencapsulated the OCPs to blind the treatment and then sent them to the research site. To preserve the blinding, we overencapsulated the commercially purchased intact gestodene 0.075-mg and ethinyl E2 20-microgram OCPs and identical-appearing placebo pills. Adherence was assessed with pill counts confirmed at each visit. The research pharmacy also kept the randomization list. Both participants and care providers in the study were blinded to the treatment. The patients were randomized into the study group of continuous OCPs and the control group of cyclic OCPs based on a randomization table with a block size of four, known only by the biostatistician. Patients in the continuous group received 28 active pills (0.075-mg gestodene and 20-microgram ethinyl E2, a monophasic OCP), whereas patients in the cyclic OCP group received 21 active pills and 7 placebo pills. Gestodene-containing oral contraceptives currently are not available in United States; however, they are marketed in Croatia, where the study was conducted (and we chose this because we wanted a low-dose ethinyl E2 pill and this was the only 20-microgram ethinyl E2 available in Croatia).
Participants were in good health, their age was 18 -35 years, and they had a history of primary dysmenorrhea (onset less than 3 years after menarche). They had regular (25-31 days) menstrual cycles for the 3-month period preceding enrollment, with symptoms of moderate to severe primary dysmenorrhea during those cycles. The pain associated with primary dysmenorrhea was abdominal or pelvic, could radiate to the back and along the thighs, could begin up to 1 day before menses, and could last for the first 3 days of bleeding. The pain could be accompanied with systemic symptoms, including nausea, vomiting, diarrhea, headache, fatigue, nervousness, and dizziness.
Exclusion criteria were contraindications to OCP therapy (as described in the drug label), known or suspected secondary dysmenorrhea (major abdominal or pelvic surgery, endometriosis, pelvic inflammatory disease, ovarian cysts, pathological vaginal secretion, chronic abdominal pain, inflammatory bowel disease, irritable bowel syndrome), concomitant treatment with OCPs, gonadotropin-releasing hormone agonists and antagonists, antiandrogens, gonadotro-pins, and antiobesity drugs, the use of contraceptive implants, injectable contraceptives or intrauterine devices (the washout period on all these medications was 3 months), smoking (because we were uncertain about the risk-benefit of continuous OCP use in this population), migraine, increased severity of headaches, depression requiring hospitalization or associated with suicidal ideation during previous estrogen or OCP use, and known or suspected hypersensitivity to trial drug. Patients enrolled simultaneously into other investigative studies that require medications or otherwise prevent compliance with the protocol were also excluded.
Patients had a screening visit in which inclusion and exclusion criteria were determined and informed consent signed, a randomization visit, and three study visits (after 1 month, 3 months, and 6 months). At the screening visit, patients were asked to define pain they were feeling for the past three cycles, on a categorical scale presented, as none, mild, moderate, or severe. They were allowed to participate in the study if they rated their pain as moderate or severe. The first two OCP boxes were dispensed at the randomization visit, and patients were advised to take one pill daily (and two pills if a day was missed) starting on the first day of their next period.
At first study visit, scheduled between days 25 and 28 of the study, visual analog scale and Moos Menstrual Distress Questionnaire were administered for current bleeding, if it happened, and for previous bleeding at days 1-4 of the study. Other visits were scheduled at days 53-56, 81-84, and 165-168 of the study. Participants kept vaginal bleeding diaries that were reviewed at each study visit. On each page of the bleeding diary, patients had three pictures of sanitary pads and three pictures of tampons (for analysis they were named spotting, moderate, and heavy bleeding), indicating the amount of blood staining. They were asked to make a mark for each pad or tampon they have used that had blood staining that was similar to that shown in the picture, underneath the appropriate picture, and across from the correct date. Color Doppler ultrasonography also was performed at each study visit using an Aloka 2000 color Doppler ultrasonography with 7.5-MHz vaginal transducer. The scanning technique was as follows: after excluding uterine and ovarian pathology with the conventional ultrasonography, uterine arteries were visualized laterally in the transverse section of the cervicocorporeal junction. Measurements of the pulsatility index (pulsatility indexϭmaximal systolic flowϪminimal diastolic flow/mean flow) were made after at least three consecutive blood flow velocity waveforms were analyzed.
The primary outcome was the difference in subjective perception of pain as measured by the visual Cyclic oral contraceptives n=19
Continuous oral contraceptives n=19
Dropped out in Month 1* (changed her mind about participation in study) n=1
Dropped out in Month 3 (adverse effects: nausea and weight gain) n=1
Dropped out in Month 3 (adverse effects: weight gain) n=1
Dropped out between Months 3 and 6 (no reason specifi ed) n=2
Dropped out between Months 3 and 6 (adverse effects: weight gain; other: no reason specifi ed) n=2
Completed the study n=14
Completed the study n=15 Fig. 1 . Flow of participants through the study. *Nϭ3 participants who did not return for a follow-up visit after randomization and were excluded from the analysis per the modified intent-to-treat (mITT) approach.
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analog scale over a period of 6 months, whereas the secondary outcomes were the differences in menstrualrelated symptoms as determined by Moos Menstrual Distress Questionnaire and in ultrasound parameters (endometrial thickness, uterine artery pulsatility index). The visual analog scale is a validated pain scale 10 used widely in clinical trials assessing the intensity of pain, especially in trials with patients with primary dysmenorrhea. The visual analog scale uses an analog linear scale to assess pain intensity. The scale is 100 mm long; the extremes of the scale are to the left ("no pain") and to the right ("worst pain I have ever felt"). A score itself is determined by measuring the distance from the left side of the scale to the point that the patient marked.
At baseline, at 3 months, and at 6 months, patients completed the Moos Menstrual Distress Questionnaire, 11 a validated questionnaire of menstrual-related symptoms that is often used in the dysmenorrhea trials. In a questionnaire, patients are asked to quantify their symptoms related to the cycle for 4 days before the current bleeding, for the time of the bleeding, and for the rest of the cycle, describing it as 0 (no experience of symptom), 1 (present, mild), 2 (present, moderate), 3 (present, strong), and 4 (present, severe).
A modified intention-to-treat approach, defined before study initiation, was used for efficacy analyses. The predefined modified intention-to-treat approach included for analysis all participants who used the medication they were randomized to and who recorded at least one primary outcome score after the dose. Baseline values were not imputed or carried forward. All analyses were performed using SAS statistical software.
Linear mixed-effects models were fit to the data to assess between-group (treatment regimen) and withingroup differences over time for all continuous outcomes. 12 The independent variables for these models were treatment regimen, time (month), and the interaction of treatment regimen and time. From these linear mixed-effects models that included the two main effects and their interaction, contrasts were constructed to assess changes from baseline to each specific postrandomization month to compare within and between the treatment regimens. The linear mixed-effects models used a spatial power law covariance structure to account for unequally spaced repeated measurements (ie, visits) over time. 13 Poisson regression models were fit to assess differences in treatment regimens with respect to bleeding day outcomes, in which bleeding days were represented as the total number of bleeding days over the 6-month study time interval. Effect sizes from the Poisson regression models were quantified using rate ratios 14 and 95% confidence intervals (CIs).
We estimated that 38 participants would be needed to detect a 30-mm difference in visual analog scale between the continuous and cyclic 21-7 OCP treatment regimens with 90% power using a two-sided test having a significance level of 0.05. The power calculation assumed a visual analog scale standard deviation (SD) of 25 mm and factored in an anticipated 15% participant dropout for the trial.
RESULTS
Forty-three women were screened, 38 were randomized, and 29 completed the study (Fig. 1) . Three of the 38 randomized women never returned for a postdose visit assessment and therefore were excluded in the modified intention-to-treat analysis. Baseline descriptives are presented in Table 1 . There were no significant changes from baseline between the two groups after 6 months of treatment for any of the following blood tests: bilirubin, alkaline phosphatase, alanine aminotransferase, glucose, total cholesterol, low-density lipoprotein, high-density lipoprotein, triglycerides, thyroid-stimulating hormone, T3, T4, blood urea nitrogen, creatinine, and complete blood count. Mean visual analog scale score (SD) in the cyclic regimen was 64.4 (SD 31.9) at screening visit, 19.0 (SD 24.8) after 1 month, and 5.2. (SD 9.5) at the end of the study. Mean visual analog scale score in the continuous group was 75.6 (SD 16.7) at screening visit, 3.1 (SD 5.8) after 1 month, and 0.8 (SD 1.4) at the end of the study. In both groups, pain reduction measured by visual analog scale was significant compared with baseline ( Table 2 ). The continuous regimen was superior to the cyclic regimen when comparing pain reduction after 1 and 3 months of treatment, and had marginal statistical significance after 6 months of treatment (Fig. 2) .
The changes in Moos Menstrual Distress Questionnaire scores over time were the same for the continuous and cyclic groups, with no changes between the groups (Table 2) . We did note a significant increase in weight and body mass index (calculated as weight (kg)/[height (m)] 2 ), and a decrease in systolic blood pressure at 6 months between the study groups (all PϽ.05; Table 3 ). There were no significant changes from baseline between the two groups after 6 months of treatment for ovarian volume and endometrial thickness, or for uterine artery resistance and pulsatility indices (data not shown). Within both groups, there was a significant decrease in endometrial thickness after 6 months of treatment (continuous: Ϫ3.7, 95% CI Ϫ5.4 to Ϫ2.0, PϽ.001; cyclic: Ϫ3.4, 95% CI Ϫ5.2 to Ϫ1.7, PϽ.001), with no difference between treatments. We observed more bleeding and spotting days in continuous compared with cyclic regimens over the period of 6 months, as shown in Table 4 .
DISCUSSION
This is a randomized trial of continuous compared with cyclic OCPs in the treatment of primary dysmenorrhea. Our results show that in healthy young women, both regimens of OCPs are effective in the treatment of primary dysmenorrhea at 6 months, although the continuous OCP regimen is superior in pain relief compared with cyclic OCPs in the short term (up to 3 months), with no differences in quality of life as determined by the Moos Menstrual Distress Questionnaire between groups. Further, we noted in the continuous group greater weight gain and more bleeding or spotting days, but a decrease in systolic blood pressure compared with the cyclic group.
Dysmenorrhea has been successfully treated with OCPs. Davis et al 15 assessed whether a low-dose OCP is more effective than placebo treatment for dysmenorrhea pain in adolescents, and they reported that the mean Moos Menstrual Distress Questionnaire pain score was lower (less pain) in the OCP group than the placebo group, comparable with our findings in both groups. Our findings also are consistent with other studies of other gynecologic disorders with chronic pain. For instance, several studies addressed the use of a continuous OCP regimen in patients with endometriosis, which is associated with pelvic pain, dysmenorrhea, dyspareunia, and infertility. [7] [8] [9] They found less endometriosis-associated dysmenorrhea in the continuous contraceptive groups, which is comparable with our findings. Kwiecien et al, 16 in a study of bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose OCP, examined symptoms of menstrual pain. At the conclusion of the study, participants completed a satisfaction questionnaire, and significantly less menstrual pain was noted in the continuous group.
Under social, cultural, and religious influences, women traditionally have been prescribed OCPs in a pattern of 21 days of active pills with 7 days of inactive pills as a way of mimicking the natural menstrual cycle. 17 However, in dysmenorrhea patients, this may attenuate the full pain benefit of OCPs. The continuous administration may reduce dysmenorrhea by eliminating withdrawal bleeding and associated uterine contractions, as well as by preventing rebound ovarian function during the pill-free interval, which may stimulate the growth of the endometrium. 18 Previous studies in other populations have shown greater satisfaction and quality of life with extended cycle regimens. 19 -21 A multicenter randomized trial 22 of an extended-cycle OCP assessed patient satisfaction with the continuous regimen. Patients reported a preference for the reduced frequency of menstrual periods, and that they would prefer to have fewer menstrual periods after completion of the study.
We found no or only modest differences between the groups in premenstrual and intermenstrual symptoms that constitute the Moos Menstrual Distress Questionnaire, which is different from other studies. 18, 23 However, some studies did not find that OCP use alters the incidence or severity of premenstrual change in Moos Menstrual Distress Questionnaire. 24 The reason for this 
Fig. 2.
Comparisons between the two groups in visual analog scale scores (VAS) at varying time points in the study. Asterisks signify that all P-values were rounded to two decimal places. The P-value for the comparison at 6 months was rounded to 0.05; however, it is actually slightly larger than 0.05, which is why it was reported that after 6 months only marginal statistical significance was reached. 
